Alzheimer Disease Clinical Trials in Houston, Texas

5 studies are recruiting for alzheimer disease in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   The University of Texas Health Science Center at Houston, Houston, Texas

   Locations

   62 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1261, Houston, Texas

   Locations

   296 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

3. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   Local Institution - 0020, Houston, Texas

   Locations

   77 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

4. Epidemiology and Biomarker Study in Alzheimer's Disease

   Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

   Stage

   Phase 3

   Ages

   55 to 75

   Site

   Care Access - Houston, Houston, Texas

   Locations

   4 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07142954 on ClinicalTrials.gov

5. Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

   Inflammation occurs in many brain diseases including Alzheimer's disease. In Alzheimer's disease, an abnormal protein called amyloid starts accumulating decades before the start of forgetfulness. However, scientists have reported that inflammation but not amyloid is linked to forgetfulness and the …

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Houston Methodist Research Institute, Houston, Texas

   Run by

   The Methodist Hospital Research Institute

   See if you can join NCT05582200 on ClinicalTrials.gov